Pharmacologic control of CAR-T cell function using dasatinib

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447

Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048], Blood, 124, 188, 10.1182/blood-2014-05-552729

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Neelapu, 2018, Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148

Hoyos, 2010, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, 24, 1160, 10.1038/leu.2010.75

Gargett, 2014, The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells, Front Pharmacol, 5, 235, 10.3389/fphar.2014.00235

Diaconu, 2017, Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells, Mol Ther, 25, 580, 10.1016/j.ymthe.2017.01.011

Schade, 2008, Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation, Blood, 111, 1366, 10.1182/blood-2007-04-084814

Blake, 2008, The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro, Clin Immunol, 127, 330, 10.1016/j.clim.2008.02.006

Weichsel, 2008, Profound inhibition of antigen-specific T-cell effector functions by dasatinib, Clin Cancer Res, 14, 2484, 10.1158/1078-0432.CCR-07-4393

Lee, 2010, Lck is a key target of imatinib and dasatinib in T-cell activation, Leukemia, 24, 896, 10.1038/leu.2010.11

Davenport, 2018, Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity, Proc Natl Acad Sci USA, 115, E2068, 10.1073/pnas.1716266115

Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal, 11, eaat6753, 10.1126/scisignal.aat6753

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838

Barrett, 2011, Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling, Blood, 118, e112, 10.1182/blood-2011-04-346528

Sotillo, 2015, Convergence of Acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020

Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Giavridis, 2018, CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade, Nat Med, 24, 731, 10.1038/s41591-018-0041-7

Norelli, 2018, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells, Nat Med, 24, 739, 10.1038/s41591-018-0036-4

Singh, 2017, Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function, Cytotherapy, 19, 867, 10.1016/j.jcyt.2017.04.001

Dasatinib: dosing/administration (2018). In: Micromedex (lane.stanford.edu) [electronic version]. Ann Arbor, MI: Truven Health Analytics. http://www.micromedexsolutions.com/. Accessed 16 September 2018.

Demetri, 2009, Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors, Clin Cancer Res, 15, 6232, 10.1158/1078-0432.CCR-09-0224

Pennell, 2018, Human CD19-targeted mouse T-cells induce B-cell aplasia and toxicity in human CD19 transgenic mice, Mol Ther J Am Soc Gene Ther, 26, 1423, 10.1016/j.ymthe.2018.04.006

Porkka, 2008, Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia, Blood, 112, 1005, 10.1182/blood-2008-02-140665